Organovo is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. The Company is pursuing multiple IND-track programs to develop its NovoTissuesÂŽ to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Organovoâs first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA. In order to support its plan to initiate multiple IND-track programs, the Company is providing access to its ExVive⢠in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovoâs wholly-owned subsidiary, Samsara Sciences, provides the Company and its clients with high quality human liver and kidney cells for research applications. Organovois changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Source
